Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.65 |
| ▸ | MME | P08473 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11853819 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL30625385 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL29372832 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL9308524 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL3361183 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL10448989 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL17157280 | 1.00 | KMT2A (0.67) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL30052812 | 0.98 | KMT2A (0.64) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL30288025 | 0.98 | KMT2A (0.64) | KMT2AKDM4EMEN1LMNAMPO | |
| SCHEMBL29578686 | 0.97 | LTA4H (0.65) | KMT2AKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766545-B1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) | 2023-08-16 | — | — | EP | claimed |
| CN-113514518-B | Preparation method of hydrogen peroxide sensor based on polypeptide-enzyme composite material | 江苏大学 | 2023-05-09 | — | — | CN | claimed |
| CN-113533279-B | Method for detecting enrofloxacin by using fluorescent dipeptide nano microspheres/nucleic acid aptamer | 河北农业大学 | 2022-07-29 | — | — | CN | claimed |
| US-20220168206-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) | 2022-06-02 | — | — | US | claimed |
| CN-114182358-A | Anti-tau protein fluorescent polypeptide nanoparticle array, preparation method and application | 西北工业大学 | 2022-03-15 | — | — | CN | claimed |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | ACTICOR BIOTECH (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250302953-A1 | METHODS OF TREATING PATIENTS EXHIBITING A PRIOR FAILED THERAPY WITH HYPOIMMUNOGENIC CELLS | SANA BIOTECHNOLOGY, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-3507303-B1 | CD20 ANTIBODIES | TIGATX INC (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025104204-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES IN SUBPOPULATIONS OF SUBJECTS | ACTICOR BIOTECH (FR) | 2025-05-22 | — | — | WO | disclosed |
| EP-4556492-A1 | TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES IN SUBPOPULATIONS OF SUBJECTS | Acticor Biotech (FR) | 2025-05-21 | — | — | EP | disclosed |
| EP-4091628-A1 | NOVEL ANTI-HUMAN GPVI ANTIBODIES AND USES THEREOF | Acticor Biotech (FR) | 2022-11-23 | — | — | EP | disclosed |
| US-11442059-B2 | Method for treating a chronic itch condition by administering small molecule MrgprX4 antagonists | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| US-11414495-B2 | CD20 antibodies | TIGA TX, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-108289939-B | Anti-human GPVI antibodies and uses thereof | 艾科迪科尔生物技术公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-113533279-B | Method for detecting enrofloxacin by using fluorescent dipeptide nano microspheres/nucleic acid aptamer | 河北农业大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-3331553-B1 | NOVEL ANTI-HUMAN GPVI ANTIBODIES AND USES THEREOF | ACTICOR BIOTECH (FR) | 2022-06-29 | — | — | EP | disclosed |
| US-20220168206-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| CN-114182358-A | Anti-tau protein fluorescent polypeptide nanoparticle array, preparation method and application | 西北工业大学 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11442059-B2 | Method for treating a chronic itch condition by administering small molecule MrgprX4 antagonists | MRGPRX4, MRGPRX2, MRGPRX1 | KMT2A 2775/4885KDM4E 2984/4885MEN1 3452/4885 |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | SPPL2B, SPPL2A, CRYZ | KMT2A 4735/4885KDM4E 4295/4885MEN1 2863/4885 |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | MAX, CRYZ, STAMBP | KMT2A 4620/4885KDM4E 4268/4885MEN1 2817/4885 |
| US-12630631-B2 | Inhibition of platelet aggregation using anti- human gpvi antibodies | IGLV6-57, GP6, VSIG8 | KMT2A 4118/4885KDM4E 4430/4885MEN1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.